#1 Clinical Trials Search in Europe

Allogeneic Faecal Microbiota, Pooled

This article examines several clinical trials investigating the use of allogeneic faecal microbiota, a type of microbiome-based therapy, for treating various medical conditions. These trials aim to assess the safety, efficacy, and optimal dosing of faecal microbiota transplantation (FMT) in capsule or enema form for conditions like non-alcoholic steatohepatitis, diverticulitis, ulcerative colitis, Crohn’s disease, and diabetes management after bariatric surgery. The studies range from Phase II to Phase III trials and involve comparing FMT to placebo or standard treatments.

Table of Contents

Introduction

Allogeneic faecal microbiota, pooled, also known as pooled allogeneic faecal microbiota, is an innovative medical treatment that involves transplanting fecal matter from healthy donors to patients suffering from various gastrointestinal and metabolic disorders. This treatment, commonly referred to as Fecal Microbiota Transplantation (FMT), aims to restore a healthy balance of gut bacteria in patients whose microbiome has been disrupted[1].

What is Fecal Microbiota Transplantation (FMT)?

FMT is a procedure in which fecal matter, or stool, is collected from a healthy donor, processed, and then transferred to a recipient. The goal is to introduce healthy bacterial flora into the recipient’s digestive system. This treatment is based on the growing understanding of the crucial role that gut microbiota plays in human health and various disease processes[2].

Conditions Being Studied

Clinical trials are currently investigating the use of allogeneic faecal microbiota for several conditions:

  • Non-alcoholic steatohepatitis (NASH): A type of fatty liver disease not caused by alcohol consumption[1].
  • Complications in patients with blood cancer undergoing stem cell transplantation: FMT is being studied to prevent complications such as graft-versus-host disease (GvHD)[2].
  • Axial spondyloarthritis: A type of inflammatory arthritis that primarily affects the spine and sacroiliac joints[3].
  • Recurring diverticulitis: Inflammation or infection of small pouches (diverticula) that can form in the digestive system[4].
  • Crohn’s disease: A type of inflammatory bowel disease[5].
  • Ulcerative colitis: Another form of inflammatory bowel disease[6].
  • Type 2 diabetes: Particularly in patients who have undergone bariatric surgery but have not achieved diabetes remission[7].

How is it Administered?

Allogeneic faecal microbiota can be administered in several ways:

  • Oral capsules: The fecal microbiota is processed into capsules that patients can swallow[1].
  • Enema: The fecal microbiota is prepared as a liquid suspension and administered rectally[6].
  • Colonoscopy: In some cases, the fecal microbiota may be introduced directly into the colon during a colonoscopy procedure[5].

The method of administration may vary depending on the specific condition being treated and the design of the clinical trial.

Efficacy and Potential Benefits

While research is still ongoing, early studies suggest that FMT may have several potential benefits:

  • Improvement in liver health for patients with NASH[1].
  • Reduced risk of complications in patients undergoing stem cell transplantation[2].
  • Potential reduction in inflammation and disease activity in inflammatory conditions like axial spondyloarthritis, Crohn’s disease, and ulcerative colitis[3].
  • Possible reduction in the frequency of acute diverticulitis episodes[4].
  • Potential improvement in glycemic control in patients with type 2 diabetes[7].

It’s important to note that these potential benefits are still being studied, and more research is needed to fully understand the efficacy of FMT for these conditions.

Safety and Side Effects

As with any medical treatment, FMT carries potential risks and side effects. Common side effects may include:

  • Abdominal pain
  • Nausea
  • Vomiting
  • Fever
  • Changes in bowel habits

More serious complications, while rare, can include infections. To minimize risks, donors are carefully screened for infectious diseases and other health conditions[2].

Ongoing Research

Several clinical trials are currently underway to further investigate the efficacy and safety of allogeneic faecal microbiota transplantation for various conditions. These studies aim to:

  • Determine optimal dosing regimens
  • Assess long-term efficacy and safety
  • Identify characteristics of “good responders” to the treatment
  • Understand changes in gut microbiota composition following FMT
  • Evaluate the impact on quality of life for patients

The results of these ongoing studies will provide valuable insights into the potential of FMT as a treatment option for various gastrointestinal and metabolic disorders[6].

Conclusion

Allogeneic faecal microbiota transplantation represents an exciting frontier in medical research. While still in the investigational stages for many conditions, it shows promise as a potential treatment for a range of gastrointestinal and metabolic disorders. As research continues, we may gain a better understanding of how manipulating the gut microbiome can impact overall health and specific disease processes. Patients interested in FMT should consult with their healthcare providers and consider participating in clinical trials to access this innovative treatment approach.

Trial Focus Medical Condition Treatment Form Trial Phase Key Objectives
NASH Treatment Non-alcoholic Steatohepatitis Oral Capsules (MBK-01) Phase II Assess efficacy and safety of FMT capsules vs placebo
Hematopoietic Cell Transplantation Hematologic Malignancies Oral Capsules (MaaT033) Phase IIb Evaluate FMT to prevent complications in stem cell transplantation
Axial Spondyloarthritis Axial Spondyloarthritis Oral Capsules (MaaT033) Phase II Assess FMT efficacy in patients resistant to conventional treatment
Recurrent Diverticulitis Recurring Diverticulitis Oral Capsules (MBK-01) Phase IIa Determine optimal dosage and assess efficacy and safety
Crohn’s Disease Management Crohn’s Disease Oral Capsules and Enema Phase III Evaluate FMT as maintenance treatment after anti-TNF withdrawal
Ulcerative Colitis Treatment Ulcerative Colitis Enema Phase III Compare FMT vs sham transplantation for steroid-free remission
Diabetes Management Post-Bariatric Surgery Type 2 Diabetes Oral Capsules Not Specified Assess FMT efficacy on HbA1c levels in non-diabetic remission patients

FAQ

  • What is allogeneic faecal microbiota? Allogeneic faecal microbiota is a type of microbiome-based therapy that involves transferring fecal material from healthy donors to patients. It contains a diverse community of beneficial gut bacteria and is being studied as a potential treatment for various medical conditions.
  • What medical conditions are being studied in these clinical trials? The clinical trials are investigating the use of allogeneic faecal microbiota for conditions such as non-alcoholic steatohepatitis (NASH), recurrent diverticulitis, ulcerative colitis, Crohn's disease, and diabetes management in patients who have undergone bariatric surgery.
  • How is the faecal microbiota administered in these trials? The faecal microbiota is administered in different forms across the trials, including oral capsules (e.g., MaaT033, MBK-01) and enemas. The specific method of administration varies depending on the study and the condition being treated.
  • What are the main objectives of these clinical trials? The main objectives of these trials include assessing the safety and efficacy of faecal microbiota transplantation, determining optimal dosing regimens, evaluating its impact on disease symptoms and progression, and comparing its effects to placebo or standard treatments.
  • How long do these clinical trials typically last? The duration of these clinical trials varies, but many of them involve follow-up periods ranging from several months to up to 2 years. This allows researchers to assess both short-term and long-term effects of the treatment.

Ongoing Clinical Trials on Allogeneic Faecal Microbiota, Pooled

  • Study on Fecal Microbiota Transfer for Better Diabetes Control in Adults with Type 2 Diabetes After Bariatric Surgery

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Fecal Microbiota Transplantation for Crohn’s Disease Patients in Remission After Stopping Anti-TNF Therapy

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Oral Fecal Microbiota Transplantation in Patients Colonized with Multi-Drug Resistant Bacteria

    Recruiting

    3 1
    Investigated drugs:
    France

  • Study on MaaT033 and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-1/PD-L1 Blockade Due to Antibiotic Use

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on Fecal Microbiome Transplantation for Patients with Decompensated Cirrhosis Using Allogeneic Fecal Microbiota Capsules

    Recruiting

    3 1
    Investigated drugs:
    Spain

  • Study on Fecal Microbiota Transplantation for Patients with Axial Spondyloarthritis Resistant to Conventional Treatment

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on MBK-01 and Drug Combination for Treating Patients with Recurrent Diverticulitis

    Recruiting

    2 1 1 1
    Investigated drugs:
    Spain

  • Study on MaaT033 to Prevent Complications in Patients with Blood Cancer Undergoing Stem Cell Transplantation

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany The Netherlands Spain

  • Study of Fecal Microbiota Transplantation in Capsule Form Compared to Placebo for Patients with Severe Irritable Bowel Syndrome

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    France

  • Safety and Efficacy of MaaT013 with Vancomycin in Children and Adolescents with Gastrointestinal Acute Graft‑versus‑Host Disease

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    France Italy The Netherlands Spain

Glossary

  • Allogeneic Faecal Microbiota: A type of microbiome-based therapy that involves transferring fecal material containing beneficial gut bacteria from healthy donors to patients for therapeutic purposes.
  • Fecal Microbiota Transplantation (FMT): A medical procedure in which fecal matter from a healthy donor is transferred to a recipient to treat certain gastrointestinal conditions or restore the gut microbiome.
  • Non-alcoholic Steatohepatitis (NASH): A type of fatty liver disease characterized by inflammation and liver cell damage, which can lead to fibrosis and cirrhosis.
  • Diverticulitis: An inflammation or infection in one or more small pouches (diverticula) that can form in the digestive tract, most commonly in the colon.
  • Ulcerative Colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, primarily affecting the colon and rectum.
  • Crohn's Disease: A type of inflammatory bowel disease that causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
  • Bariatric Surgery: A group of surgical procedures performed on the stomach or intestines to induce weight loss in severely obese individuals.
  • Microbiome: The collection of all microorganisms, including bacteria, viruses, and fungi, that naturally live on and in our bodies, particularly in the gut.
  • Placebo: A substance or treatment with no active therapeutic effect, used as a control in clinical trials to test the effectiveness of another drug or treatment.
  • HbA1c: Glycated hemoglobin, a form of hemoglobin used to test average blood glucose levels over a period of months, commonly used in diagnosing and monitoring diabetes.
  • Endoscopic Remission: A state in which there is no visible inflammation or ulceration in the digestive tract when examined through an endoscope.
  • Clinical Remission: The absence of symptoms or signs of a disease, often used in the context of inflammatory bowel diseases like Crohn's disease or ulcerative colitis.
  • Dysbiosis: An imbalance in the gut microbiome, where there is a disruption in the normal composition of microorganisms.
  • Metagenomic Analysis: A method of analyzing genetic material recovered directly from environmental samples, used to study the composition and diversity of microbial communities.

References

  1. http://clinicaltrials.eu/trial/study-on-fecal-microbiota-capsules-vs-placebo-for-treating-non-alcoholic-steatohepatitis-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-maat033-to-prevent-complications-in-patients-with-blood-cancer-undergoing-stem-cell-transplantation/
  3. http://clinicaltrials.eu/trial/study-on-fecal-microbiota-transplantation-for-patients-with-axial-spondyloarthritis-resistant-to-conventional-treatment/
  4. http://clinicaltrials.eu/trial/study-on-mbk-01-and-drug-combination-for-treating-patients-with-recurrent-diverticulitis/
  5. http://clinicaltrials.eu/trial-id/2024-511822-30-00
  6. http://clinicaltrials.eu/trial-id/2024-511863-27-01
  7. http://clinicaltrials.eu/trial-id/2024-511870-65-00